FOLH1 and prostate cancer: It seems that in the case of treatment of ccRCC with [177Lu]Lu-EB-PSMA-617 the ratio of the dose absorbed by the neoplastic lesions to the toxic doses received by the critical organs will be even more unfavorable than in the case of prostate cancer, due to the different location of PSMA (on the surface of the neovascular endothelium in the cases of ccRCC and on the surface of the cancer cell in the case of prostate cancer), and that this direction of research on the use of PSMA ligands in the treatment of renal cancer will also turn out to be a dead end.